{
  "trial_id": "NCT00795600",
  "trial_group": "obesity",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Sex, Body Mass Index (BMI), Duration of Type 2 Diabetes, Glycosylated Haemoglobin (HbA1c), Total Daily Insulin Dose, Use of Metformin, Baseline Trunk Fat Mass, Baseline Peripheral Fat Ratio, Cardiac Disease History, Retinopathy or Maculopathy History, Previous Use of Weight Lowering Pharmacotherapy, Previous Surgical Treatment of Obesity, Recent Use of Investigational Drug.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex"
        ],
        [
          "Duration of diabetes",
          "Duration of Type 2 Diabetes"
        ],
        [
          "retinopathy (common risk factor in uncontrolled diabetes)",
          "Retinopathy or Maculopathy History"
        ],
        [
          "Total daily insulin dose higher or equal 2 IU/kg",
          "Total Daily Insulin Dose"
        ],
        [
          "Use of approved weight lowering pharmacotherapy",
          "Previous Use of Weight Lowering Pharmacotherapy"
        ],
        [
          "Previous or planned surgical treatment of obesity",
          "Previous Surgical Treatment of Obesity"
        ],
        [
          "Receipt of any investigational drug within 1 month prior to this trial",
          "Recent Use of Investigational Drug"
        ],
        [
          "Glycosylated haemoglobin (HbA1c)",
          "Glycosylated Haemoglobin (HbA1c)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Diabetic complication at baseline",
        "nephropathy (common risk factor in uncontrolled diabetes)",
        "neuropathy (common risk factor in uncontrolled diabetes)",
        "macroangiopathy"
      ],
      "remaining_candidate_features": [
        "Body Mass Index (BMI)",
        "Use of Metformin",
        "Baseline Trunk Fat Mass",
        "Baseline Peripheral Fat Ratio",
        "Cardiac Disease History"
      ]
    },
    "processed-gen-response": "Age, Sex, Body Mass Index (BMI), Duration of Type 2 Diabetes, Glycosylated Haemoglobin (HbA1c), Total Daily Insulin Dose, Use of Metformin, Baseline Trunk Fat Mass, Baseline Peripheral Fat Ratio, Cardiac Disease History, Retinopathy or Maculopathy History, Previous Use of Weight Lowering Pharmacotherapy, Previous Surgical Treatment of Obesity, Recent Use of Investigational Drug."
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Body Mass Index, Baseline HbA1c, Duration of Diabetes, Total Daily Insulin Dose, Systolic Blood Pressure, Diastolic Blood Pressure, Trunk Fat Mass,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Duration of diabetes",
          "Duration of Diabetes"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Diabetic complication at baseline",
        "nephropathy (common risk factor in uncontrolled diabetes)",
        "neuropathy (common risk factor in uncontrolled diabetes)",
        "retinopathy (common risk factor in uncontrolled diabetes)",
        "macroangiopathy"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Body Mass Index",
        "Baseline HbA1c",
        "Total Daily Insulin Dose",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Trunk Fat Mass"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, Race/Ethnicity, Region of Enrollment, Body Mass Index, Baseline HbA1c, Duration of Diabetes, Total Daily Insulin Dose, Systolic Blood Pressure, Diastolic Blood Pressure, Trunk Fat Mass"
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "##Answer:\nAge, Continuous, Sex: Female, Male, BMI, HbA1c, Diabetes duration, Total daily insulin dose, Region of Enrollment, Previous cardiovascular disease, Hypertension, Dyslipidaemia,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Duration of diabetes",
          "Diabetes duration"
        ],
        [
          "retinopathy (common risk factor in uncontrolled diabetes)",
          "Total daily insulin dose"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Diabetic complication at baseline",
        "nephropathy (common risk factor in uncontrolled diabetes)",
        "neuropathy (common risk factor in uncontrolled diabetes)",
        "macroangiopathy"
      ],
      "remaining_candidate_features": [
        "BMI",
        "HbA1c",
        "Previous cardiovascular disease",
        "Hypertension",
        "Dyslipidaemia"
      ]
    },
    "processed-gen-response": "Age, Sex: Female, Male, BMI, HbA1c, Diabetes duration, Total daily insulin dose, Region of Enrollment, Previous cardiovascular disease, Hypertension, Dyslipidaemia"
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), glycosylated haemoglobin (HbA1c), total daily insulin dose, duration of diabetes, duration of insulin treatment, type of insulin treatment prior to inclusion, metformin use, smoking status, systolic and diastolic blood pressure, lipid profile, history of cardiac disease, history of proliferative retinopathy or maculopathy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Duration of diabetes",
          "duration of diabetes"
        ],
        [
          "retinopathy (common risk factor in uncontrolled diabetes)",
          "history of proliferative retinopathy or maculopathy."
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment",
        "Diabetic complication at baseline",
        "nephropathy (common risk factor in uncontrolled diabetes)",
        "neuropathy (common risk factor in uncontrolled diabetes)",
        "macroangiopathy"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "glycosylated haemoglobin (HbA1c)",
        "total daily insulin dose",
        "duration of insulin treatment",
        "type of insulin treatment prior to inclusion",
        "metformin use",
        "smoking status",
        "systolic and diastolic blood pressure",
        "lipid profile",
        "history of cardiac disease"
      ]
    },
    "processed-gen-response": "Age, sex, race, ethnicity, body mass index (BMI), glycosylated haemoglobin (HbA1c), total daily insulin dose, duration of diabetes, duration of insulin treatment, type of insulin treatment prior to inclusion, metformin use, smoking status, systolic and diastolic blood pressure, lipid profile, history of cardiac disease, history of proliferative retinopathy or maculopathy."
  }
}